Merck Vioxx Sales Will Fall Short Of High Expectations, Firm Says
Merck's Vioxx sales are showing the impact of a slower penetration rate of COX-2 inhibitors into the analgesic market, the company said June 22.
Merck's Vioxx sales are showing the impact of a slower penetration rate of COX-2 inhibitors into the analgesic market, the company said June 22.